Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Effects of N-acetyl cysteine on cognitive function in bipolar disorder.

Dean OM, Bush AI, Copolov DL, Kohlmann K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Berk M.

Psychiatry Clin Neurosci. 2012 Oct;66(6):514-7. doi: 10.1111/j.1440-1819.2012.02392.x.

2.

N-acetyl cysteine for depressive symptoms in bipolar disorder--a double-blind randomized placebo-controlled trial.

Berk M, Copolov DL, Dean O, Lu K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Bush AI.

Biol Psychiatry. 2008 Sep 15;64(6):468-75. doi: 10.1016/j.biopsych.2008.04.022. Epub 2008 Jun 5.

PMID:
18534556
3.

N-acetyl cysteine add-on treatment for bipolar II disorder: a subgroup analysis of a randomized placebo-controlled trial.

Magalhães PV, Dean OM, Bush AI, Copolov DL, Malhi GS, Kohlmann K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Berk M.

J Affect Disord. 2011 Mar;129(1-3):317-20. doi: 10.1016/j.jad.2010.08.001. Epub 2010 Aug 30.

PMID:
20800897
4.

A randomized, double-blind, controlled trial evaluating the effect of intranasal insulin on neurocognitive function in euthymic patients with bipolar disorder.

McIntyre RS, Soczynska JK, Woldeyohannes HO, Miranda A, Vaccarino A, Macqueen G, Lewis GF, Kennedy SH.

Bipolar Disord. 2012 Nov;14(7):697-706. doi: 10.1111/bdi.12006.

PMID:
23107220
5.

Relation between cigarette smoking and cognitive function in euthymic individuals with bipolar disorder.

Law CW, Soczynska JK, Woldeyohannes HO, Miranda A, Brooks JO 3rd, McIntyre RS.

Pharmacol Biochem Behav. 2009 Mar;92(1):12-6. doi: 10.1016/j.pbb.2008.10.002. Epub 2008 Oct 22.

PMID:
18976682
6.

Randomized placebo-controlled adjunctive study of an extract of withania somnifera for cognitive dysfunction in bipolar disorder.

Chengappa KN, Bowie CR, Schlicht PJ, Fleet D, Brar JS, Jindal R.

J Clin Psychiatry. 2013 Nov;74(11):1076-83. doi: 10.4088/JCP.13m08413.

7.

The effect of overweight/obesity on cognitive function in euthymic individuals with bipolar disorder.

Yim CY, Soczynska JK, Kennedy SH, Woldeyohannes HO, Brietzke E, McIntyre RS.

Eur Psychiatry. 2012 Apr;27(3):223-8. doi: 10.1016/j.eurpsy.2011.02.004. Epub 2011 May 12.

PMID:
21570263
8.

Neuropsychological performance in euthymic Indian patients with bipolar disorder type I: correlation between quality of life and global functioning.

Pattanayak RD, Sagar R, Mehta M.

Psychiatry Clin Neurosci. 2012 Dec;66(7):553-63. doi: 10.1111/j.1440-1819.2012.02400.x.

9.

Neuropsychological performance in bipolar I, bipolar II and unipolar depression patients: a longitudinal, naturalistic study.

Xu G, Lin K, Rao D, Dang Y, Ouyang H, Guo Y, Ma J, Chen J.

J Affect Disord. 2012 Feb;136(3):328-39. doi: 10.1016/j.jad.2011.11.029. Epub 2011 Dec 12.

PMID:
22169253
10.

A preliminary investigation on the efficacy of N-acetyl cysteine for mania or hypomania.

Magalhães PV, Dean OM, Bush AI, Copolov DL, Malhi GS, Kohlmann K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Berk M.

Aust N Z J Psychiatry. 2013 Jun;47(6):564-8. doi: 10.1177/0004867413481631. Epub 2013 Mar 14.

PMID:
23493756
11.

Executive function and attention span in euthymic patients with bipolar 1 disorder.

Normala I, Abdul HA, Azlin B, Nik Ruzyanei NJ, Hazli Z, Shah SA.

Med J Malaysia. 2010 Sep;65(3):199-203.

12.

Neurocognitive function in clinically stable men with bipolar I disorder or schizophrenia and normal control subjects.

Altshuler LL, Ventura J, van Gorp WG, Green MF, Theberge DC, Mintz J.

Biol Psychiatry. 2004 Oct 15;56(8):560-9.

PMID:
15476685
13.

Cognitive impairment in a Brazilian sample of patients with bipolar disorder.

Schneider JJ, Candiago RH, Rosa AR, Ceresér KM, Kapczinski F.

Rev Bras Psiquiatr. 2008 Sep;30(3):209-14. Erratum in: Rev Bras Psiquiatr. 2008 Dec;30(4):432.

14.

RESEARCH: Cognitive rehabilitation for bipolar disorder: An open trial for employed patients with residual depressive symptoms.

Deckersbach T, Nierenberg AA, Kessler R, Lund HG, Ametrano RM, Sachs G, Rauch SL, Dougherty D.

CNS Neurosci Ther. 2010 Oct;16(5):298-307. doi: 10.1111/j.1755-5949.2009.00110.x.

15.

Systemic illness moderates the impact of N-acetyl cysteine in bipolar disorder.

Magalhães PV, Dean OM, Bush AI, Copolov DL, Weisinger D, Malhi GS, Kohlmann K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Berk M.

Prog Neuropsychopharmacol Biol Psychiatry. 2012 Apr 27;37(1):132-5. doi: 10.1016/j.pnpbp.2011.11.011. Epub 2011 Dec 23.

PMID:
22212173
16.

Long-term stability of cognitive impairment in bipolar disorder: a 2-year follow-up study of lithium-treated euthymic bipolar patients.

Mur M, Portella MJ, Martínez-Arán A, Pifarré J, Vieta E.

J Clin Psychiatry. 2008 May;69(5):712-9.

PMID:
18435565
17.

Cognitive functioning in elderly patients with early onset bipolar disorder.

Schouws SN, Zoeteman JB, Comijs HC, Stek ML, Beekman AT.

Int J Geriatr Psychiatry. 2007 Sep;22(9):856-61.

PMID:
17262882
18.

N-acetylcysteine for major depressive episodes in bipolar disorder.

Magalhães PV, Dean OM, Bush AI, Copolov DL, Malhi GS, Kohlmann K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Berk M.

Rev Bras Psiquiatr. 2011 Dec;33(4):374-8.

19.

Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder.

Young AH, Gallagher P, Watson S, Del-Estal D, Owen BM, Ferrier IN.

Neuropsychopharmacology. 2004 Aug;29(8):1538-45.

20.

Persistent neuropsychological deficit in euthymic bipolar patients: executive function as a core deficit.

Mur M, Portella MJ, Martínez-Arán A, Pifarré J, Vieta E.

J Clin Psychiatry. 2007 Jul;68(7):1078-86.

PMID:
17685745

Supplemental Content

Support Center